EFFECT OF BIOACTIVE COMPOUNDS FROM СORNUS MAS L. FRUITS ON THE LEVEL OF ADVANCED GLYCATION END-PRODUCTS (AGEs) AND RECEPTORS FOR AGEs IN BLOOD PLASMA AND LEUKOCYTES OF RATS WITH STREPTOZOTOCIN-INDUCED DIABETES MELLITUS

Iryna Brodyak, Nataliia Sybirna


DOI: http://dx.doi.org/10.30970/sbi.2002.885

Abstract


Background. Мetabolic distortions mediated сhronic hyperglycemia lead to pathophysiological alterations in diabetes mellitus. Persistent elevation of blood glucose promotes non-enzymatic glycation of proteins and lipids, leading to the accumulation of advanced glycation end-products (AGEs). Accumulation of AGEs reflects impaired metabolic clearance and/or excretion and is therefore considered a marker of both long-term glycemic control and oxidative-carbonyl stress in tissues. The biological effects of AGEs are largely mediated through their interaction with the receptor for advanced glycation end products (RAGE), triggering pro-inflammatory signaling pathways. Accordingly, this study investigated the effects of bioactive compounds extracted from сornelian cherry fruits (Cornus mas L.) on AGEs and RAGEs levels in plasma and blood leukocytes of rats with experimental diabetes mellitus.
Materials and Methods. Experiments were conducted in streptozotocin-induced diabetic rats divided into three experimental groups. Starting on day 10 after diabetes induction, animals received oral administration of fruit extracts from сornelian cherry cultivars ‘Podolski’, ‘Yantarnyi’ & ‘Flava’, as well as the iridoid glycoside loganic acid isolated from these fruits, at a dose of 20 mg/kg body weight for 14 consecutive days. Control and untreated diabetic rats received distilled water (1 mL per rat) by oral gavage. On day 24 of the experiment, blood samples were collected. Levels of fluorescent and non-fluorescent AGEs were determined in plasma and leukocytes. Full-length receptor for AGEs (flRAGE) expression in leukocyte membranes was assessed using an indirect immunoperoxidase assay, while plasma concentrations of the soluble form of RAGE (sRAGE) were measured by immunoblotting.
Results. One of the mechanisms of the deleterious effect of high glucose level, in particular its ability to react non-enzymatically with proteins with the formation of AGEs, has been studied. An increase for AGEs in blood plasma of rats with diabetes was found, instead, interesting results were obtained, indicating a decrease in the fluorescent and non-fluorescent AGEs level in leukocytes. This is likely due to impaired leukocyte glucose uptake in condition of diabetic hypoinsulinemia. There was a significant increase in the number of RAGEs+ leukocytes and the level of sRAGEs in plasma of rats with diabetes. It was found that the content of the fluorescent and non-fluorescent AGEs significantly increased in leukocytes of rats with DM after administration of the fruit extracts of the cornelian cherry ‘Podolski’ and ‘Yantarnyi‘ & ‘Flava‘ cultivars, and the loganic acid. It is worth noting that the extract from the fruits of Cornus mas L. ‘Podolski’ cultivar showed the best effect among all studied extracts and led to reduce the level of AGEs in the blood plasma and receptors to them.
Conclusions. The fruit extract of Cornus mas L. ‘Podolski’ cultivar demonstrates therapeutic potential in the correction of impaired glucose metabolism in diabetes mellitus. The beneficial effects of the extract’s bioactive compounds are associated with the inhibition of glycation, the formation of AGEs, and normalize the level of RAGEs in blood plasma and leukocytes.


Keywords


experimental diabetes mellitus, fruit extracts of cornelian cherry, loganic acid, leukocytes, blood plasma, markers of oxidative-carbonyl stress, AGEs, RAGEs

Full Text:

PDF

References


Alba-Loureiro, T. C., Munhoz, C. D., Martins, J. O., Cerchiaro, G. A., Scavone, C., Curi, R., & Sannomiya, P. (2007). Neutrophil function and metabolism in individuals with diabetes mellitus. Brazilian Journal of Medical and Biological Research, 40(8), 1037-1044. doi:10.1590/s0100-879x2006005000143
CrossrefPubMedGoogle Scholar

Anwar, S., Khan, S., Almatroudi, A., Khan, A. A., Alsahli, M. A., Almatroodi, S. A., & Rahmani, A. H. (2021). A review on mechanism of inhibition of advanced glycation end products formation by plant derived polyphenolic compounds. Molecular Biology Reports, 48(1), 787-805. doi:10.1007/s11033-020-06084-0
CrossrefPubMedGoogle Schola

Bayram, H. M., & Arda Ozturkcan, S. (2020). Bioactive components and biological properties of cornelian cherry (Cornus mas L.): a comprehensive review. Journal of Functional Foods, 75, 104252. doi:10.1016/j.jff.2020.104252
CrossrefGoogle Scholar

Brodyak, I., Moroz, A., Bernacka, K., Kucharska, A. Z., & Sybirna, N. (2025). Alleviation of hyperglycaemia and oxidative stress by fruit extracts of different cultivars of the cornelian cherry (Cornus mas L. and Cornus mas × Cornus officinalis) in rats with diabetes mellitus. Food & Function, 16(5), 2136-2155. doi:10.1039/d4fo05426a
CrossrefPubMedGoogle Schola

Cecerska-Heryć, E., Engwert, W., Michałów, J., Marciniak, J., Birger, R., Serwin, N., Heryć, R., Polikowska, A., Goszka, M., Wojciuk, B., Wiśniewska, M., & Dołęgowska, B. (2025). Oxidative stress markers and inflammation in type 1 and 2 diabetes are affected by BMI, treatment type, and complications. Scientific Reports, 15(1), 23605. doi:10.1038/s41598-025-05818-z
CrossrefPubMedPMCGoogle Scholar

Challier, M., Jacqueminet, S., Benabdesselam, O., Grimaldi, A., & Beaudeux, J.-L. (2005). Increased serum concentrations of soluble receptor for advanced glycation end products in patients with type 1 diabetes. Clinical Chemistry, 51(9), 1749-1750. doi:10.1373/clinchem.2005.051961
CrossrefPubMedGoogle Scholar

Chen, J.-H., Lin, X., Bu, C., & Zhang, X. (2018). Role of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategies. Nutrition & Metabolism, 15(1), 72. doi:10.1186/s12986-018-0306-7
CrossrefPubMedPMCGoogle Scholar

Dariya, B., & Nagaraju, G. P. (2020). Advanced glycation end products in diabetes, cancer and phytochemical therapy. Drug Discovery Today, 25(9), 1614-1623. doi:10.1016/j.drudis.2020.07.003
CrossrefPubMedGoogle Scholar

Dong, H., Zhang, Y., Huang, Y., & Deng, H. (2022). Pathophysiology of RAGE in inflammatory diseases. Frontiers in Immunology, 13, 931473. doi:10.3389/fimmu.2022.931473
CrossrefPubMedPMCGoogle Scholar

Dzydzan, O., Brodyak, I., Sokół-Łętowska, A., Kucharska, A. Z., & Sybirna, N. (2020). Loganic acid, an iridoid glycoside extracted from Cornus mas L. fruits, reduces of carbonyl/oxidative stress biomarkers in plasma and restores antioxidant balance in leukocytes of rats with streptozotocin-induced diabetes mellitus. Life, 10(12), 349. doi:10.3390/life10120349
CrossrefPubMedPMCGoogle Scholar

Erusalimsky, J. D. (2021). The use of the soluble receptor for advanced glycation-end products (sRAGE) as a potential biomarker of disease risk and adverse outcomes. Redox Biology, 42, 101958. doi:10.1016/j.redox.2021.101958
CrossrefPubMedPMCGoogle Scholar

Gallucci, S. (2016). An overview of the innate immune response to infectious and noninfectious stressors. In M. Amadori (Ed.), The innate immune response to noninfectious stressors (Ch. 1, pp. 1-24). Academic Press. doi:10.1016/b978-0-12-801968-9.00001-5
CrossrefGoogle Scholar

Goh, S.-Y., & Cooper, M. E. (2008). The role of advanced glycation end products in progression and complications of diabetes. The Journal of Clinical Endocrinology & Metabolism, 93(4), 1143-1152. doi:10.1210/jc.2007-1817
CrossrefPubMedGoogle Scholar

Heier, M., Margeirsdottir, H. D., Gaarder, M., Stensæth, K. H., Brunborg, C., Torjesen, P. A., Seljeflot, I., Hanssen, K. F., & Dahl-Jørgensen, K. (2015). Soluble RAGE and atherosclerosis in youth with type 1 diabetes: a 5-year follow-up study. Cardiovascular Diabetology, 14(1), 126.doi:10.1186/s12933-015-0292-2
CrossrefPubMedPMCGoogle Scholar

Holst, B., & Williamson, G. (2008). Nutrients and phytochemicals: from bioavailability to bioefficacy beyond antioxidants. Current Opinion in Biotechnology, 19(2), 73-82. doi:10.1016/j.copbio.2008.03.003
CrossrefPubMedGoogle Scholar

Kato, S., Matsumura, T., Sugawa, H., & Nagai, R. (2024). Correlation between serum advanced glycation end-products and vascular complications in patient with type 2 diabetes. Scientific Reports, 14(1), 18722. doi:10.1038/s41598-024-69822-5
CrossrefPubMedPMCGoogle Scholar

Khalid, M., Petroianu, G., & Adem, A. (2022). Advanced glycation end products and diabetes mellitus: mechanisms and perspectives. Biomolecules, 12(4), 542. doi:10.3390/biom12040542
CrossrefPubMedPMCGoogle Scholar

Khangholi, S., Majid, F. A., Berwary, N. J., Ahmad, F., & Aziz, R. B. (2016). The mechanisms of inhibition of advanced glycation end products formation through polyphenols in hyperglycemic condition. Planta Medica, 82(1-2), 32-45. doi:10.1055/s-0035-1558086
CrossrefPubMedGoogle Scholar

Lamprea-Montealegre, J. A., Arnold, A. M., McCLelland, R. L., Mukamal, K. J., Djousse, L., Biggs, M. L., Siscovick, D. S., Tracy, R. P., Beisswenger, P. J., Psaty, B. M., Ix, J. H., & Kizer, J. R. (2022). Plasma levels of advanced glycation endproducts and risk of cardiovascular events: findings from 2 prospective cohorts. Journal of the American Heart Association, 11(15), e024012. doi:10.1161/jaha.121.024012
CrossrefPubMedPMCGoogle Scholar

Lang, F., Singh, Y., Salker, M. S., Ma, K., Pandyra, A. A., Lang, P. A., & Lang, K. S. (2020). Glucose transport in lymphocytes. Pflügers Archiv - European Journal of Physiology, 472(9), 1401-1406. doi:10.1007/s00424-020-02416-y
CrossrefPubMedGoogle Scholar

Lowry, O. H., Rosebrough, N. J., Farr, A. L., & Randall, R. J. (1951). Protein measurement with the Folin phenol reagent. The Journal of Biological Chemistry, 193(1), 265-275. doi:10.1016/s0021-9258(19)52451-6
CrossrefPubMedGoogle Scholar

Luo, X., Wu, J., Jing, S., & Yan, L. J. (2016). Hyperglycemic stress and carbon stress in diabetic glucotoxicity. Aging and Disease, 7(1), 90-110. doi:10.14336/ad.2015.0702
CrossrefPubMedPMCGoogle Scholar

Maratou, E., Dimitriadis, G., Kollias, A., Boutati, E., Lambadiari, V., Mitrou, P., & Raptis, S. A. (2007). Glucose transporter expression on the plasma membrane of resting and activated white blood cells. European Journal of Clinical Investigation, 37(4), 282-290. doi:10.1111/j.1365-2362.2007.01786.x
CrossrefPubMedGoogle Scholar

Nomi, Y., Kudo, H., Miyamoto, K., Okura, T., Yamamoto, K., Shimohiro, H., Kitao, S., Ito, Y., Egawa, S., Kawahara, K., Otsuka, Y., & Ueta, E. (2020). Free advanced glycation end product distribution in blood components and the effect of genetic polymorphisms. Biochimie, 179, 69-76. doi:10.1016/j.biochi.2020.09.010
CrossrefPubMedGoogle Scholar

Putta, S., & Kilari, E. K. (2015). A review on methods of estimation of advanced glycation end products. World Journal of Pharmaceutical Research, 4, 689-699.
Google Scholar

Rhee, S. Y., & Kim, Y. S. (2018). The role of advanced glycation end products in diabetic vascular complications. Diabetes & Metabolism Journal, 42(3), 188-195. doi:10.4093/dmj.2017.0105
CrossrefPubMedPMCGoogle Scholar

Rodrigues Oliveira, S. M., Rebocho, A., Ahmadpour, E., Nissapatorn, V., & de Lourdes Pereira, M. (2023). Type 1 diabetes mellitus: a review on advances and challenges in creating insulin producing devices. Micromachines, 14(1), 151. doi:10.3390/mi14010151
CrossrefPubMedPMCGoogle Scholar

Ruiz, H., Ramasamy, R., & Schmidt, A. M. (2020). Advanced glycation end products: building on the concept of the "Common soil" in metabolic disease. Endocrinology, 161(1), bqz006. doi:10.1210/endocr/bqz006
CrossrefPubMedPMCGoogle Scholar

Shen, C.-Y., Lu, C.-H., Wu, C.-H., Li, K.-J., Kuo, Y.-M., Hsieh, S.-C., & Yu, C.-L. (2020). The development of Maillard reaction, and advanced glycation end product (AGE)-receptor for age (RAGE) signaling inhibitors as novel therapeutic strategies for patients with AGE-related diseases. Molecules, 25(23), 5591. doi:10.3390/molecules25235591
CrossrefPubMedPMCGoogle Scholar

Thomas, M. C., Söderlund, J., Lehto, M., Mäkinen, V. P., Moran, J. L., Cooper, M. E., Forsblom, C., & Groop, P. H. (2011). Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes. Diabetologia, 54(10), 2669-2677. doi:10.1007/s00125-011-2186-5
CrossrefPubMedGoogle Scholar

Thornalley, P. J., & Rabbani, N. (2011). Protein damage in diabetes and uremia - identifying hotspots of proteome damage where minimal modification is amplified to marked pathophysiological effect. Free Radical Research, 45(1), 89-100. doi:10.3109/10715762.2010.534162
CrossrefPubMedGoogle Scholar

Twarda-Clapa, A., Olczak, A., Białkowska, A. M., & Koziołkiewicz, M. (2022). Advanced glycation end-products (AGEs): formation, chemistry, classification, receptors, and diseases related to AGEs. Cells, 11(8), 1312. doi:10.3390/cells11081312
CrossrefPubMedPMCGoogle Scholar

Vrhovac, I., Breljak, D., & Sabolić, I. (2014). Glucose transporters in the mammalian blood cells. Periodicum Biologorum, 116(2), 131-138.
Google Scholar

Wang, B., Jiang, T., Qi, Y., Luo, S., Xia, Y., Lang, B., Zhang, B., & Zheng, S. (2025). AGE-RAGE axis and cardiovascular diseases: pathophysiologic mechanisms and prospects for clinical applications. Cardiovascular Drugs and Therapy, 39(6), 1489-1506. doi:10.1007/s10557-024-07639-0
CrossrefPubMedPMCGoogle Scholar

Yeh, W.-J., Hsia, S.-M., Lee, W.-H., & Wu, C.-H. (2017). Polyphenols with antiglycation activity and mechanisms of action: a review of recent findings. Journal of Food and Drug Analysis, 25(1), 84-92. doi:10.1016/j.jfda.2016.10.017
CrossrefPubMedPMCGoogle Scholar


Refbacks

  • There are currently no refbacks.


Copyright (c) 2026 Iryna Brodyak, Nataliia Sybirna

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.